眾生藥業(002317.SZ):擬9000萬元轉讓仲強藥業100%股權予上海雍威
格隆匯 8 月 24日丨眾生藥業(002317.SZ)公佈,根據公司戰略規劃,為進一步提高資產使用效率,優化公司產業佈局,公司於2020年8月23日召開第七屆董事會第六次會議,全體董事一致審議通過了《關於轉讓子公司股權的議案》,同意公司將持有的廣東仲強藥業有限公司(“仲強藥業”)100%股權以人民幣9000萬元轉讓給上海雍威生物科技有限公司(“上海雍威”)。同意授權公司董事長根據具體情況實施相關事宜。
根據公司戰略規劃,為進一步提高資產使用效率,優化公司產業佈局,增加公司投資收益。此次交易預計增加1672萬元的投資收益。此次交易不會影響公司生產經營活動的正常運行,不會對公司財務及經營狀況產生不利影響,有助於提高公司資產使用效率,優化公司產業佈局,有利於公司盤活存量資產,符合公司戰略佈局與未來規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.